Protein 'Fingerprint' may predict ovarian cancer relapse
NCT ID NCT00086567
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 25 times
Summary
This study aims to create a blood test that can predict when ovarian, peritoneal, or fallopian tube cancer might come back after remission. Researchers will look at proteins in the blood to find a pattern, or 'fingerprint,' linked to relapse. 119 women with stage III or IV cancer in first remission took part, with regular check-ups and scans over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cedars Sinai Medical Center
Los Angeles, California, 90048-1804, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Evanston Northwestern University Hospital
Evanston, Illinois, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Massachusetts General Hospital, Dana Farber
Boston, Massachusetts, 02114, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
New York University School of Medicine
New York, New York, 10016, United States
-
Pacific Ovarian Cancer Research Consortium at FHCRC
Seattle, Washington, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Washington/Fred Hutchinson Cancer Research Center
Seattle, Washington, 28104, United States
Conditions
Explore the condition pages connected to this study.